Two-weeks repeated-dose oral toxicity study of Pediococcus acidilactici J9 in a mice model
- PDF / 1,498,253 Bytes
- 14 Pages / 595.276 x 790.866 pts Page_size
- 78 Downloads / 173 Views
RESEARCH ARTICLE
Open Access
Two-weeks repeated-dose oral toxicity study of Pediococcus acidilactici J9 in a mice model Mijung Lee1, Jin-Young Chung2, Ka Yeun Kim3, Wooseok Im1,4* and Manho Kim1,4,5*
Abstract Background: Helicobacter pylori (H. pylori) is an important pathogen that causes chronic gastritis and peptic ulcer, and is related to the development of gastric carcinoma. Several chemicals, including antibiotics, have been used to eradicate H.pylori. However, more studies are yet requred to accomplish a sufficient therapy. Pediococcus acidilactici (P. acidilactici) J9 were studied for inhibition of binding of H.pylori binding to human gastric cell lines. This study was performed in order to investigate the repeated-dose toxicity of P. acidilactici J9 in male and female mice. Results: C57BL/6 male and female Mus musculus were divided into four groups (n = 10 in each group). P. acidilactici J9 was administered daily by oral injection of vehicle control at dosage levels to a low-dose group (500 mg/kg/day), middle-dose group (1000 mg/kg/day), and high-dose group (2000 mg/kg/day) for 2 weeks. After 14 days of exposure, the blood biochemistry and hematology were investigated, along with a histopathology exam. There were no bacterial-related deaths or abnormal clinical signs in either gender of mouse. The data was observed during the period in terms of body weight, food intake, and water consumption. Also, no alterations in organ weights upon administration of P. acidilactici J9 alone were observed. The adhesion and growth of H. pylori were inhibited by a 24 h treatment of H. pylori and P. acidilactici J9 on adenocarcinoma gastric (AGS) cells, which are gastric cancer cells. Compared to the control group (AGS cell and H. pylori), the number of H. pylori analyzed by FACS significantly (p < 0.01) decreased after incubation of AGS cell with P. acidilactici J9 for 24 h. Conclusions: These results suggest that the oral application of P. acidilactici J9, up to a dosage level of 2000 mg/ kg/day, causes no adverse effects in both male and female mice. P. acidilactici J9 inhibits the adhesion of H.pylori to AGS cancer cells. When used as probiotics, P. acidilactici J9 may help decrease the occurrence of gastritis and reduce the risk of H.pylori infection with promising safety issues. Keywords: Pediococcus acidilactici J9, Repeated two-week oral dose toxicity, Mouse, Helicobacter pylori, AGS cell
Background Lactobacillus is a gram-positive microorganism that utilizes carbohydrates as the energy source and produces organic acids like lactic acid and acetic acid as final products. It is used industrially in various fermented products, like fermented vegetables and dairy products, * Correspondence: [email protected]; [email protected] 1 Department of Neurology, Biomedical Research Institute, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, South Korea Full list of author information is available at the end of the article
which are broadly involved in the everyday life [1, 2]. Lactobacillus dete
Data Loading...
